Skip to main content

Table 3 Antibody responses in patients vaccinated with 100 μg or 200 μg of CHP-NY-ESO-1

From: Dose-dependent effects of NY-ESO-1 protein vaccine complexed with cholesteryl pullulan (CHP-NY-ESO-1) on immune responses and survival benefits of esophageal cancer patients

100 μg 200 μg
pt No. Vaccination cycle Baseline (dilution titer) Antibody response (cycle*) pt No. Vaccination cycle Baseline (dilution titer) Antibody response (cycle*)
100-01 9 negative responded(4) 200-01 15 negative responded(2)
100-02 3 negative no response** 200-02 9 negative responded(2)
100-03 3 negative no response** 200-03 8 positive (x1,600) responded(5)
100-04 7 negative no response 200-04 21 negative responded(2)
100-05 2 negative no response 200-05 3 negative responded(2)
100-06 16 positive (x6,400) responded(1) 200-06 10 positive (x400) responded(1)
100-07 9 positive (x25,600) no response 200-07 3 positive (x25,600) responded(2)**
100-08 10 negative responded(1) 200-08 11 positive (x400) responded(1)
100-09 5 negative no response 200-09 18 positive (x400) responded(3)
100-10 27 positive (x400) responded(3) 200-10 11 positive (x400) responded(2)
100-11 8 negative responded(2) 200-11 3 positive (x400) responded(2)
100-12 8 negative responded(2) 200-12 9 negative responded(1)
100-13 26 negative responded(2)     
antibody response rate 53.8%*** 100%***
  1. *vaccine cycles with which antibody responses appeared. **antibody responses assayed after two vaccinations.***p = 0.015(Fisher’s exact test).